Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 24 Apr 2023
Adding mint flavor to e-cigarette liquids increases the amount of vapour particles produced and is linked, according to a recent study published in Respiratory Research.
Read Full NewsModelling shows fewer cases and deaths with screening starting at age 45 years.
A phase 3 trial examines whether carfilzomib-lenalidomide-dexamethasone maintenance therapy improves disease control compared with lenalidomide alone in patients with multiple myeloma.
Although many surgeons avoid it, nipple-sparing mastectomy after radiation is a feasible alternative to skin-sparing mastectomy and may help preserve patients’ psychological well-being.
1.
Future of Lab-Developed Tests Still Taking Shape
2.
High Success Rate With Conversion Therapy for Unresectable Gastroesophageal Cancer
3.
Scientists Employ Technology to Identify Plagiarism and Forgeries in Published Studies.
4.
Charles III, King of Kings, is Cancerous.
5.
Enhanced access for patients with prostate cancer is provided by the new SPECT/CT technique, which demonstrates remarkable biomarker identification.
1.
Understanding the Silent Threat: Unveiling Prostate Cancer Symptoms
2.
Unveiling the Mysteries of Smudge Cells: A New Frontier in Cellular Biology
3.
Exploring the Pleomorphic Adenoma: A Unique and Varied Tumor
4.
Unleashing the Power of Immune Triads: A Novel Approach to Cancer Immunotherapy
5.
Frontiers in Cancer Therapeutics: U.S. Oncology Trials and Drug Discovery Trends
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Complexities of Ph Negative ALL - Part VII
2.
What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?
3.
The Landscape of First-Line Treatment for Urothelial Carcinoma- Further Discussion
4.
Key Takeaways from The CROWN Trial For ALK + NSCLC Patients with CNS Diseases
5.
Nimotozumab Plus Chemo-radiotherapy v/s Placebo Plus Chemo-radiotherapy in Locally Advanced Nasopharyngeal Carcinoma
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge